Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. MicroRNA expression profiling of carcinoma in situ (CIS) cells of the testis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Molecular signatures of thyroid follicular neoplasia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Intrapancreatic accessory spleen mimicking malignant tumor: three case reports

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Markers of bone turnover are reduced in patients with CF related diabetes; the role of glucose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Relation between invasive hemodynamics and measured glomerular filtration rate by 51Cr-EDTA clearance in advanced heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Esben Andreas Carlsen
  • Nicola Fazio
  • Dan Granberg
  • Simona Grozinsky-Glasberg
  • Hojjat Ahmadzadehfar
  • Chiara Maria Grana
  • Wouter T Zandee
  • Jaroslaw Cwikla
  • Martin A Walter
  • Peter Sandor Oturai
  • Anja Rinke
  • Andrew Weaver
  • Andrea Frilling
  • Sara Gritti
  • Anne Kirstine Arveschoug
  • Amichay Meirovitz
  • Ulrich Knigge
  • Halfdan Sorbye
Vis graf over relationer

Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1-2 (G1-G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN G3) is largely unknown. We therefore aimed to assess the benefits and side effects of PRRT in patients with GEP NEN G3. We performed a retrospective cohort study at 12 centers to assess the efficacy and toxicity of PRRT in patients with GEP NEN G3. Outcomes were response rate, disease control rate, progression-free survival (PFS), overall survival (OS) and toxicity. We included 149 patients (primary tumor: pancreatic n = 89, gastrointestinal n = 34, unknown n = 26). PRRT was first-line (n = 30), second-line (n = 62) or later-line treatment (n = 57). Of 114 patients evaluated, 1% had complete response, 41% partial response, 38% stable disease and 20% progressive disease. Of 104 patients with documented progressive disease before PRRT, disease control rate was 69%. The total cohort had median PFS of 14 months and OS of 29 months. Ki-67 21-54% (n = 125) vs Ki-67 ≥55% (n = 23): PFS 16 vs 6 months (P < 0.001) and OS 31 vs 9 months (P < 0.001). Well (n = 60) vs poorly differentiated NEN (n = 62): PFS 19 vs 8 months (P < 0.001) and OS 44 vs 19 months (P < 0.001). Grade 3-4 hematological or renal toxicity occurred in 17% of patients. This large multicenter cohort of patients with GEP NEN G3 treated with PRRT demonstrates promising response rates, disease control rates, PFS and OS as well as toxicity in patients with mainly progressive disease. Based on these results, PRRT may be considered for patients with GEP NEN G3.

OriginalsprogEngelsk
TidsskriftEndocrine-Related Cancer
Vol/bind26
Udgave nummer2
Sider (fra-til)227-239
Antal sider13
ISSN1351-0088
DOI
StatusUdgivet - 1 feb. 2019

ID: 56462953